Trade Medpace Holdings Inc - MEDP CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.48
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02154 %(-$1.08)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.02154%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000682 %(-$0.03)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.00068%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02154 %
  (-$1.08)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000682 %
  (-$0.03)

Key Stats

• Prev. Close: 529.02
• Open: 526.86
• 1-Year Change: 68.68%
• Day's Range: 526.86 - 539.3

Trade Medpace Holdings Inc - MEDP

About Medpace Holdings Inc

Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. It also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Medpace Holdings Inc revenues increased 23% to $1.14B. Net income applicable to common stockholders increased 25% to $181.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Amortization decrease of 35% to $5.1M (expense), Stock-based Compensation in SGA decrease of 15% to $5.1M (expense).